Source: Health Products Regulatory Authority (IE) Revision Year: 2020 Publisher: Mylan IRE Healthcare Limited, Unit 35/36, Grange Parade, Baldoyle Industrial Estate, Dublin 13, Ireland
Minocin SA 100 mg Modified Release Capsules.
| Pharmaceutical Form |
|---|
|
Modified release hard capsules. Two piece, hard shell, size 2 capsule with an orange opaque body and a brown cap containing a mixture of off white and coloured (yellow, green, brown/black) spherical pellets. |
Each capsule contains 100mg of minocycline equivalent to 116 mg of minocycline hydrochloride dihydrate.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Minocycline |
Minocycline is a semi-synthetic derivative of tetracycline. Minocycline inhibits protein synthesis in susceptible bacteria. In common with other tetracyclines it is primarily bacteriostatic and has a similar spectrum of activity to other tetracyclines. |
| List of Excipients |
|---|
|
Microcrystalline cellulose Capsule body: Titanium dioxide (E171) Capsule cap: Titanium dioxide (E171) |
PVC/PVDC aluminium blister packs containing 2, 7, 28, 49 and 56 capsules.
Polypropylene bottle with urea cap containing 100
capsules.
Not all pack sizes may be marketed.
Mylan IRE Healthcare Limited, Unit 35/36, Grange Parade, Baldoyle Industrial Estate, Dublin 13, Ireland
PA2010/060/001
Date of first authorisation: 23 June 1993
Date of last renewal: 23 June 2008
| Drug | Countries | |
|---|---|---|
| MINOCIN | Ecuador, Spain, Ireland, Malta, Mexico, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
